87 related articles for article (PubMed ID: 6677708)
1. [Interdependence between hormonal disorders, stage of development and degree of malignancy of prostatic cancer. 1].
Szymanowski J; Baranowska B; Niewiadomska A; Wysocki M; Kobuszewska-Faryna M; Zgliczynski S
J Urol (Paris); 1983; 89(8):597-600. PubMed ID: 6677708
[TBL] [Abstract][Full Text] [Related]
2. [Interdependence between hormonal disorders, staging and degree of malignancy of prostatic gland cancer. 2].
Szymanowski J; Baranowska B; Rozbicka G; Jeske W; Zgliczynski S
J Urol (Paris); 1983; 89(9):663-8. PubMed ID: 6425418
[TBL] [Abstract][Full Text] [Related]
3. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
4. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
Hsing AW; Comstock GW
Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
[TBL] [Abstract][Full Text] [Related]
5. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
6. [Hormonal disturbances in men with a prostatic adenoma (author's transl)].
Baranowska B; Zgliczynski S; Szymanowski J
J Urol (Paris); 1980; 86(7):551-8. PubMed ID: 6161196
[TBL] [Abstract][Full Text] [Related]
7. High-grade prostate cancer is associated with low serum testosterone levels.
Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
[TBL] [Abstract][Full Text] [Related]
8. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
9. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
10. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
Mo ZN; Huang X; Zhang SC; Yang JR
J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
[TBL] [Abstract][Full Text] [Related]
11. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
[TBL] [Abstract][Full Text] [Related]
12. [Hormone determinations in andrology].
Frick J
Andrologia; 1980; 12(3):211-8. PubMed ID: 6778255
[TBL] [Abstract][Full Text] [Related]
13. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
14. Serum androgens: associations with prostate cancer risk and hair patterning.
Demark-Wahnefried W; Lesko SM; Conaway MR; Robertson CN; Clark RV; Lobaugh B; Mathias BJ; Strigo TS; Paulson DF
J Androl; 1997; 18(5):495-500. PubMed ID: 9349747
[TBL] [Abstract][Full Text] [Related]
15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
16. Hormonal status in prostatic disease.
Frick J; Bartsch G
Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
[No Abstract] [Full Text] [Related]
17. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
18. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
[TBL] [Abstract][Full Text] [Related]
19. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
20. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]